Cargando…

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study

BACKGROUND: Atypical antipsychotics as first-line drugs have been used in patients with schizophrenia in China and abroad. However, its safety still needs to be evaluated in a large population, especially in Chinese patients. OBJECTIVE: The main objective of this study is to evaluate the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wenjuan, Huang, Jingjing, He, Sidi, Zhang, Lei, Shen, Yifeng, Li, Huafang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871676/
https://www.ncbi.nlm.nih.gov/pubmed/33644688
http://dx.doi.org/10.1136/gpsych-2020-100289
_version_ 1783649056094945280
author Yu, Wenjuan
Huang, Jingjing
He, Sidi
Zhang, Lei
Shen, Yifeng
Li, Huafang
author_facet Yu, Wenjuan
Huang, Jingjing
He, Sidi
Zhang, Lei
Shen, Yifeng
Li, Huafang
author_sort Yu, Wenjuan
collection PubMed
description BACKGROUND: Atypical antipsychotics as first-line drugs have been used in patients with schizophrenia in China and abroad. However, its safety still needs to be evaluated in a large population, especially in Chinese patients. OBJECTIVE: The main objective of this study is to evaluate the safety and related factors of long-term atypical antipsychotic use in patients with schizophrenia in China. The secondary objective includes the long-term efficacy of atypical antipsychotics in these patients, as well as pharmacoeconomic evaluation, population pharmacokinetic studies and pharmacogenomics studies. METHODS: This study has an observational design. The atypical antipsychotics include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone, amisulpride, perospirone and clozapine. Visits occur at 0, 4, 8, 13, 26, 52, 78, 104, 130 and 156 weeks. The efficacy evaluations include symptoms, social function, recurrence rate and hospitalisation. The safety measures include physical examination, vital signs, abdominal circumference, laboratory tests (such as blood cell analysis, blood biochemical tests and serum prolactin/thyroxine levels), 12-lead ECG, extrapyramidal syndrome assessment, sexual function evaluation, medication and other adverse events. The secondary measures include the Positive and Negative Syndrome Scale, Clinical Global Impression-Severity of Illness Scale, Calgary Depression Scale for Schizophrenia, Personal and Social Performance Scale, relapse rate, drug consolidation, medical-related expenses, income, drug plasma concentration and genetic information. RESULTS: This is a large sample, non-interventional and long-term prospective clinical study designed to truly reflect the specific details of clinical practice, fully respect patients’ needs, and understand patients’ treatment intentions and actual treatment details. CONCLUSIONS: This research method details the aims, methods, study design, strengths and limitations of the study.
format Online
Article
Text
id pubmed-7871676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78716762021-02-25 Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study Yu, Wenjuan Huang, Jingjing He, Sidi Zhang, Lei Shen, Yifeng Li, Huafang Gen Psychiatr Research Methods in Psychiatry BACKGROUND: Atypical antipsychotics as first-line drugs have been used in patients with schizophrenia in China and abroad. However, its safety still needs to be evaluated in a large population, especially in Chinese patients. OBJECTIVE: The main objective of this study is to evaluate the safety and related factors of long-term atypical antipsychotic use in patients with schizophrenia in China. The secondary objective includes the long-term efficacy of atypical antipsychotics in these patients, as well as pharmacoeconomic evaluation, population pharmacokinetic studies and pharmacogenomics studies. METHODS: This study has an observational design. The atypical antipsychotics include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone, amisulpride, perospirone and clozapine. Visits occur at 0, 4, 8, 13, 26, 52, 78, 104, 130 and 156 weeks. The efficacy evaluations include symptoms, social function, recurrence rate and hospitalisation. The safety measures include physical examination, vital signs, abdominal circumference, laboratory tests (such as blood cell analysis, blood biochemical tests and serum prolactin/thyroxine levels), 12-lead ECG, extrapyramidal syndrome assessment, sexual function evaluation, medication and other adverse events. The secondary measures include the Positive and Negative Syndrome Scale, Clinical Global Impression-Severity of Illness Scale, Calgary Depression Scale for Schizophrenia, Personal and Social Performance Scale, relapse rate, drug consolidation, medical-related expenses, income, drug plasma concentration and genetic information. RESULTS: This is a large sample, non-interventional and long-term prospective clinical study designed to truly reflect the specific details of clinical practice, fully respect patients’ needs, and understand patients’ treatment intentions and actual treatment details. CONCLUSIONS: This research method details the aims, methods, study design, strengths and limitations of the study. BMJ Publishing Group 2021-02-08 /pmc/articles/PMC7871676/ /pubmed/33644688 http://dx.doi.org/10.1136/gpsych-2020-100289 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research Methods in Psychiatry
Yu, Wenjuan
Huang, Jingjing
He, Sidi
Zhang, Lei
Shen, Yifeng
Li, Huafang
Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
title Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
title_full Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
title_fullStr Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
title_full_unstemmed Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
title_short Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
title_sort safety and related factors of treatment with long-term atypical antipsychotic in chinese patients with schizophrenia: observational study
topic Research Methods in Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871676/
https://www.ncbi.nlm.nih.gov/pubmed/33644688
http://dx.doi.org/10.1136/gpsych-2020-100289
work_keys_str_mv AT yuwenjuan safetyandrelatedfactorsoftreatmentwithlongtermatypicalantipsychoticinchinesepatientswithschizophreniaobservationalstudy
AT huangjingjing safetyandrelatedfactorsoftreatmentwithlongtermatypicalantipsychoticinchinesepatientswithschizophreniaobservationalstudy
AT hesidi safetyandrelatedfactorsoftreatmentwithlongtermatypicalantipsychoticinchinesepatientswithschizophreniaobservationalstudy
AT zhanglei safetyandrelatedfactorsoftreatmentwithlongtermatypicalantipsychoticinchinesepatientswithschizophreniaobservationalstudy
AT shenyifeng safetyandrelatedfactorsoftreatmentwithlongtermatypicalantipsychoticinchinesepatientswithschizophreniaobservationalstudy
AT lihuafang safetyandrelatedfactorsoftreatmentwithlongtermatypicalantipsychoticinchinesepatientswithschizophreniaobservationalstudy